Celularity Inc (CELU)

[Renee]

CELU: effective Feb. 29,2024 a one for 10 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php

[glenn1919]

CELU............................................https://stockcharts.com/h-sc/ui?s=CELU&p=W&b=5&g=0&id=p86431144783

[subslover]

Oh, Nice! very nice. A couple of excerps from the DR's letter

we expect our advanced biomaterial products and biobanking businesses to achieve net sales percentage growth in the range of 176.1% to 193.0% for the fourth quarter 2023 compared to the fourth quarter 2022. For the full year 2023, we expect net sales percentage growth in the range of 22.7% to 26.6% compared to the full year 2022.

We anticipate shortly that we will announce our expectations for net sales in the first quarter 2024 and the full year 2024, respectively, reflecting three core focuses:


Recently, we took steps to improve our balance sheet and support the growth of our businesses. On Wednesday, 17 January, we announced the closing of two separate financing transactions in which Celularity received combined total gross proceeds of $21 million from a $6 million private placement transaction with our largest single shareholder and a $15 million loan agreement amendment with an existing lender, respectively.

[TimeFades]

Strong trend

[Invest-in-America]

CELU: Slap-that-ASK, & call it DAPHNE???!!! (See 'Chart', below!!!)

[TheFinalCD]

Celularity Releases CEO Letter to Shareholders
https://www.globenewswire.com/news-release/2024/01/18/2811877/0/en/Celularity-Releases-CEO-Letter-to-Shareholders.html

[Invest-in-America]

CELU: Chart ain't impressive, but right now it appears to want to move UPWARDS somewhat. (Hope so, since I grabbed some of this quiet little puppy, but at a LOSS right now. How LONG can this continue to run SIDEWAYS at this price?????)

[power11]

POWER11 IS ISSUING A SELL AND RUN NOW !!

[power11]

2535 IS THE LEVEL TO WATCH; YOU BREAK IT AND ADIOS AMIGOS !!!

[power11]

WE BREAK TODAY'S LOW IS YOUR SIGN TO DUMP AND RUN
AS FAST AS YOU CAN !! WE'RE VERY CLOSE !!

[power11]

TAKE YOUR PROFIT AND RUNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN

[power11]

TAKE YOUR PROFIT AND RUNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNNN

[subslover]

Dunno but with enough buying power we can break wide open imo

[Semperfiguy]

Warrant conversion. The question is why now...

[subslover]

Insider buys 21.4 mil shares @ $0.249 https://www.otcmarkets.com/filing/html?id=17188617&guid=9qJ-kH0-h3zG-hh

[Invest-in-America]

CELU: Rocket liftoff!!

"Celularity Insider Bought Shares Worth $5,331,335, According to a Recent SEC Filing"

[TommyBoyTrader9460]

$CELU
https://x.com/hannahadad8890/status/1741089988014456890?s=61

[glenn1919]

CELU......................................https://stockcharts.com/h-sc/ui?s=CELU&p=W&b=5&g=0&id=p86431144783

[Monksdream]

CELU new 52 week low

[Monksdream]

CELU new 52 week low

[Natural Trader]

are you stupid???... they just strike $45M deal

[Semperfiguy]

Looking at the 10Q they need to keep any positive news at the top of mind. I assume they are hoping that news will be the one thing that keeps investors from bailing right now seeing they have maybe 1 month of operating cash on hand.

[saigai]

released the same news again.. i guess they cant believe nobody cares.. i do

[Stewguts]

My apologies for the delayed reply. Thank you for your thoughtful and informative response. Looks like I stumbled onto this company at the most opportune time. lol

I'm liking what I see here. Possible short squeeze in the works.

Cheers

[Triple nickle]

Not stopping

[Semperfiguy]

Stew I just signed on as a field rep with a distributor of Celularity biologic matrix products. Having gone through training for those products and examining the science against the competitors I am impressed as to their differentiators and patents giving them an upper hand. The marketing for these products are just getting ramped up so the profits should start growing exponentially through 2023. They are a no brainer choice for HCPs once they are aware.

That being said, I also looked at the financials and the gene therapy side of the business since I regularly do this for many companies I invest in. Their science is very sound and I believe IF they can continue to be funded they will result in findings that change medical treatment of some cancers and immune diseases. The concern is their low cash position in this funding environment. Most investors are staying away from any biotech in today's market, but it has the biggest potential for payoff long term. It is a cash intensive business with undetermined time lines to profitability. I suggest going to the website and reading through the investor presentation if you want the full details of what they do.

[Stewguts]

Hello crudeoil24, I've kind of stumbled on to this company today and to make a long story short, I'm kind of swamped and looking to save some time. I've done some limited research and I'm by no means am I a medical expert in gene and cell therapy but I like what I've read so far. At the risk of looking lazy, I am looking to you or any other board participants for the skinny on the Celularity story. The low price is somewhat surprising.

Cheers.

[crudeoil24]

Hey, LandToSea ! CELU on my radar.

[Semperfiguy]

Hey Crude! Are you no longer following CELU? I know you from GDVM, but just stumbled across you here as I just signed on with Celularity as a field rep and figured I would look to see if there was a board for their ticker.

[crudeoil24]

SEC 424B3 > Up to 22,874,999 Shares of Class A Common Stock Issuable Upon Exercise of Warrants

Up to 129,858,855 Shares of Class A Common Stock

Up to 8,499,999 Warrants to Purchase Class A Common Stock

[crudeoil24]

Celularity Inc.'s proposed treatment for a form of leukemia has been given the U.S. Food and Drug Administration's fast-track designation, a label designed to expedite the review of the drug, the pharmaceutical company said Monday.

Florham Park, N.J.-based Celularity is developing the treatment, a non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer cell therapy, to treat acute myeloid leukemia.

Dr. Robert Hariri, Celularity's chairman and chief executive, said that the designation would help accelerate development of the drug, which he said the company believes could improve response rates for AML patients.


Write to Matt Grossman at [e-mail]


(END) Dow Jones Newswires

December 27, 2021 08:18 ET (13:18 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

[crudeoil24]

Celularity Inc. (“Celularity”) (NASDAQ:CELU), a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, and Oncternal Therapeutics, Inc. (“Oncternal”) (NASDAQ:ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced they have entered into a research collaboration to evaluate placental derived-cellular therapies targeting receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1). As part of the collaboration, Celularity will explore the use of Oncternal’s ROR1-targeted monoclonal antibody, cirmtuzumab, in combination with Celularity’s natural killer cells. ROR1 targeted chimeric antigen receptor (CAR) gene modification will also be explored in Celularity’s CYNK natural killer cell and CyCART T cell platforms in preclinical studies.

ROR1 is highly expressed by multiple solid tumors and hematological malignancies and confers both an aggressive phenotype and survival advantage to the tumor cells. Cirmtuzumab binding to ROR1 on leukemia and lymphoma cells decreases tumor cell proliferation and survival by blocking Wnt5a-induced activation, while it does not bind to adult tissues. Celularity will evaluate the use of cirmtuzumab in combination with CYNK-101, a placental derived-allogeneic NK cell therapy that has been genetically engineered to synergize with therapeutic antibodies. As part of the collaboration, Celularity will also evaluate ROR1-targeted CAR-NK and CAR-T cell therapies as extensions of its CYNK and CyCART programs, respectively.

“Our research studying ROR1 suggests the potential for a range of new targeted therapeutics, capable of addressing a wide variety of both solid tumors and hematological malignancies,” said James Breitmeyer, M.D., Ph.D., founder, President and CEO of Oncternal. “We believe that targeted cellular therapies have the potential to extend the clinical benefit of our research and improve the standard of care for patients. However, the current limitations in efficacy, safety and availability of cellular therapies hinders their broader use. Celularity’s approach, leveraging the ability of placental-derived cells to differentiate and expand, has the potential to overcome these obstacles and could potentially offer more potent, tolerable and accessible cellular medicines and, in combination with our ROR1 targeting antibodies, address the significant unmet needs of patients.”

Robert J. Hariri, M.D., Ph.D., founder, Chairperson and Chief Executive Officer of Celularity, added, “We are thrilled to enter this partnership with Oncternal to forge new therapeutic strategies for both solid tumors and hematological malignancies using our allogeneic placental-derived cell therapy product candidates with their innate stemness. Oncternal’s work has established ROR1 as an exciting target that could be utilized for the development of new and novel cellular medicines, and there is an immense potential for synergy combining two novel approaches to create exciting new pipeline candidates targeting a wide range of cancers. We look forward to working closely together to lead the next evolution of cellular medicines.”

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

[crudeoil24]

Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic T cells engineered with a chimeric antigen receptor (CAR) (CAR-T) cells, natural killer (NK) cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, infectious and degenerative diseases. It has four placental-derived allogeneic cell types: T cells, unmodified NK cells, genetically modified NK cells and ASCs, which resulted in four key cell therapeutic programs: CyCART-19, CYNK-001, CYNK-101 and APPL-001, focused on six initial indications. Its CyCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the CD19 receptor. CYNK-001 is developing for the treatment of acute myeloid leukemia (AML), a blood cancer, and for glioblastoma multiforme (GBM), a solid tumor cancer, and COVID-19.